Safety and Antitumor Activity of the Anti-Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma

被引:301
作者
Doi, Toshihiko [1 ]
Piha-Paul, Sarina A. [2 ]
Jalal, Shadia I. [3 ]
Saraf, Sanatan [4 ]
Lunceford, Jared [4 ]
Koshiji, Minori [4 ]
Bennouna, Jaafar [5 ]
机构
[1] Natl Canc Ctr East, Chiba, Japan
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
[4] Merck, Kenilworth, NJ USA
[5] Inst Cancerol Ouest, Nantes, France
关键词
SQUAMOUS-CELL CARCINOMA; CD8(+) T-CELLS; OPEN-LABEL; PD-1; EXPRESSION; CANCER; MULTICENTER; LIGAND-1; PATHWAY;
D O I
10.1200/JCO.2017.74.9846
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The anti-programmed death-1 antibody pembrolizumab was evaluated in KEYNOTE-028, a multicohort, phase IB study of patients with programmed death ligand-1 (PD-L1)-positive advanced solid tumors. Results from the esophageal carcinoma cohort are reported herein. Patients and Methods Eligible patients with squamous cell carcinoma or adenocarcinoma of the esophagus or gastro-esophageal junction in whom standard therapy failed and who had PD-L1-positive tumors received pembrolizumab 10 mg/kg every 2 weeks for up to 2 years or until confirmed disease progression or intolerable toxicity. Response was assessed every 8 weeks up to 6 months and every 12 weeks thereafter. Primary end points were safety and overall response rate, determined by investigator review per Response Evaluation Criteria in Solid Tumors (version 1.1). Results Among 83 patients with esophageal carcinoma and samples evaluable for PD-L1 expression, 37 (45%) had PD-L1-positive tumors, and 23 were enrolled. Median age was 65 years; 78% had squamous histology; and 87% received >= two prior therapies for advanced/metastatic disease. As of the data cutoff (February 20, 2017), median follow-up was 7 months (range, 1 to 33 months). Nine patients (39%) experienced treatment-related adverse events, mostcommonly decreased appetite, decreased lymphocyte count, generalized rash, and rash (two patients [9%] each). No grade 4 adverse events or deaths were attributed to pembrolizumab. Overall response rate was 30%(95% CI, 13% to 53%); median duration of response was 15months (range, 6 to 26 months). A six-gene interferon-g gene expression signature analysis suggested that delayed progression and increased response occur among pembrolizumab-treated patients with higher interferon-g composite scores. Conclusion Pembrolizumab demonstrated manageable toxicity and durable antitumor activity in patients with heavily pretreated, PD-L1-positive advanced esophageal carcinoma. (c) 2017 by American Society of Clinical Oncology
引用
收藏
页码:61 / +
页数:10
相关论文
共 31 条
[1]  
[Anonymous], 2015, J CLIN ONCOL S
[2]  
[Anonymous], 2016, NCCN Clin Pract Guidel Oncol
[3]  
[Anonymous], 2017, NATURE, V541, P169, DOI DOI 10.1038/NATURE20805
[4]  
Carter LL, 2002, EUR J IMMUNOL, V32, P634, DOI 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO
[5]  
2-9
[6]  
Cho Y, 2003, CANCER RES, V63, P1555
[7]   Current management of esophageal cancer [J].
D'Journo, Xavier Benoit ;
Thomas, Pascal Alexandre .
JOURNAL OF THORACIC DISEASE, 2014, 6 :S253-S264
[8]   Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma [J].
Derks, Sarah ;
Nason, Katie S. ;
Liao, Xiaoyun ;
Stachler, Matthew D. ;
Liu, Kevin X. ;
Bin Liu, Jie ;
Sicinska, Ewa ;
Goldberg, Michael S. ;
Freeman, Gordon J. ;
Rodig, Scott J. ;
Davison, Jon M. ;
Bass, Adam J. .
CANCER IMMUNOLOGY RESEARCH, 2015, 3 (10) :1123-1129
[9]   Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue [J].
Dolled-Filhart, Marisa ;
Locke, Darren ;
Murphy, Tiffany ;
Lynch, Frank ;
Yearley, Jennifer H. ;
Frisman, Dennis ;
Pierce, Robert ;
Weiner, Russell ;
Wu, Dianna ;
Emancipator, Kenneth .
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2016, 140 (11) :1259-1266
[10]   Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 [J].
Ferlay, Jacques ;
Soerjomataram, Isabelle ;
Dikshit, Rajesh ;
Eser, Sultan ;
Mathers, Colin ;
Rebelo, Marise ;
Parkin, Donald Maxwell ;
Forman, David ;
Bray, Freddie .
INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (05) :E359-E386